Miami, Florida – Catalyst Pharmaceuticals, Inc. recently held its Q3 2024 Earnings Conference Call on November 7, 2024, at 8:30 AM ET. During the call, key members of the company’s leadership team, including President and CEO Richard Daly, Chief Financial Officer Michael Kalb, Chief Commercial Officer Jeffrey Del Carmen, Chief Operating Officer and Chief Scientific Officer Steven Miller, and Chief Medical & Regulatory Officer Gary Ingenito, discussed the company’s financial results and business highlights for the third quarter of 2024.

Investment analysts such as Joon Lee from Truist Securities, Charles Duncan from Cantor Fitzgerald, and Samantha Semenkow from Citi Investment Research participated in the conference call to gain insights into Catalyst Pharmaceuticals’ performance and future plans.

The conference operator, Kris, facilitated the call and welcomed participants to the discussion on Catalyst Pharmaceuticals’ financial results for the third quarter of 2024. The CFO, Mike Kalb, took the lead in presenting the financial results and business highlights, with President and CEO Rich Daly and Chief Commercial Officer Jeffrey Del Carmen also contributing to the discussion. Dr. Steve Miller, the company’s Chief Operating Officer and Chief Scientific Officer, was also available for the question and answer session.

Throughout the call, the company’s representatives made forward-looking statements about expected future results, emphasizing the inherent uncertainties and risks involved in such projections. They advised caution in interpreting these statements, as they are based on current expectations, estimates, and projections that may not necessarily align with actual future performance.

In addition to discussing financial results, the leadership team also highlighted key business achievements and upcoming initiatives aimed at driving growth and innovation within Catalyst Pharmaceuticals. The Q&A session provided further insights into the company’s strategic direction and plans for continued success in the pharmaceutical industry.